Special Issue "Blood Substitutes"
A special issue of Journal of Functional Biomaterials (ISSN 2079-4983).
Deadline for manuscript submissions: 30 November 2014
Prof. Dr. Ken Olsen
Department of Chemistry, Loyola University of Chicago, 1032 W. Sheridan Rd., Chicago, IL 60660, USA
Interests: the development of polymeric hemoglobins as potential blood substitutes; developing cancer-targeted photodynamic therapy agents; understanding protein-ligand interactions through molecular dynamics simulations
The development of hemoglobin-based oxygen carriers (HBOC) as effective alternatives to blood transfusion is clearly a desirable goal. Despite the significant commercial resources that have been expended over the last several decades to achieve this end, no products have received US FDA approval. The basic science is much better understood than it was in the 1980s when the quest began. The requirements for a successful HBOC have been clearly delineated. Various side effects have inhibited further development and regulatory approval. Cardiovascular events are of particular concern, but other aspects needing investigation include the impact of HBOCs on human physiology, the routes and consequences of hemoglobin metabolism and developing new HBOCs with improved characteristics, such as prolonged functional intravascular persistence, greater stability, and a decreased propensity to generate reactive oxygen species. New biomaterials are being developed to address these problems encountered with earlier HBOCs. In some cases these are not hemoglobin-based, but may offer new solutions to the same problems faced by the HBOCs.
Prof. Dr. Ken Olsen
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. Papers will be published continuously (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are refereed through a peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Functional Biomaterials is an international peer-reviewed Open Access quarterly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 300 CHF (Swiss Francs). English correction and/or formatting fees of 250 CHF (Swiss Francs) will be charged in certain cases for those articles accepted for publication that require extensive additional formatting and/or English corrections.
Article: Monodisperse 130 kDa and 260 kDa Recombinant Human Hemoglobin Polymers as Scaffolds for Protein Engineering of Hemoglobin-Based Oxygen Carriers
J. Funct. Biomater. 2012, 3(1), 61-78; doi:10.3390/jfb3010061
Received: 3 November 2011; in revised form: 29 December 2011 / Accepted: 5 January 2012 / Published: 13 January 2012| PDF Full-text (2070 KB) | HTML Full-text | XML Full-text
Review: Biophysical Properties of Lumbricus terrestris Erythrocruorin and Its Potential Use as a Red Blood Cell Substitute
J. Funct. Biomater. 2012, 3(1), 49-60; doi:10.3390/jfb3010049
Received: 21 October 2011; in revised form: 9 December 2011 / Accepted: 24 December 2011 / Published: 6 January 2012| Cited by 1 | PDF Full-text (295 KB) | HTML Full-text | XML Full-text
Review: Molecular Design Properties of OxyVita Hemoglobin, a New Generation Therapeutic Oxygen Carrier: A Review
J. Funct. Biomater. 2011, 2(4), 414-424; doi:10.3390/jfb2040414
Received: 3 November 2011; in revised form: 3 December 2011 / Accepted: 13 December 2011 / Published: 16 December 2011| PDF Full-text (269 KB) | HTML Full-text | XML Full-text
The below list represents only planned manuscripts. Some of these manuscripts have not been received by the Editorial Office yet. Papers submitted to MDPI journals are subject to peer-review.
Type of Paper: Review
Title: Effects of Hemoglobin-Based Oxygen Carriers on Blood Coagulation
Authors: Jonathan S. Jahr and Randall Holtby
Abstract: For many decades, HBOCs have been central to the development of resuscitation agents that provide oxygen delivery in addition to simple volume expansion. Since 80% of the world population lives in areas where fresh blood products are not available, the application of these products could prove to be highly beneficial (Kim and Greenburg 2006). Many improvements have been made to earlier generation HBOCs, but various concerns still remain, including coagulopathy, nitric oxide scavenging, platelet interference and decreased calcium concentration secondary to volume expansion (Jahr et al. 2013). This review will summarize the current challenges faced in developing HBOCs that can be used clinically, in order to guide future research efforts in the field
Type of Paper: Article
Title: Replacement of 1-2 Unit Blood Transfusion with Supra-Perfusion Inducing PEG-Albumin Plasma Expanders That Increase Blood Oxygen delivery Capacity
Authors: Amy G. Tsai, Beatriz Y. Salazar Vázquez, Pedro Cabrales, Erik B. Kistler, Daniel M. Tartakovsky, Shankar Subramaniam, Seetharama A. Acharya, Marcos Intaglietta
Abstract: At least 1/3 of the blood supply is used to transfuse only limited amounts of blood (1-2 units packed red blood cells (PRBCs) and virtually all clinical trials carried out with blood substitutes have been made at this level of oxygen carrying capacity (OCC) restoration. However, the increase of oxygenation achieved is usually marginal or non-existent, also due to the lingering vasoactivity of hemoglobin (Hb) molecular formulations. These results led to formulating “oxygen therapeutics” that target oxygen delivery to anoxic areas; however it is not clear how such a product treats the functional causes for local anoxia, which include anemia, obstruction, vasoconstriction, under-perfusion, and extremely small OCC microvascular flow (since the systemic increase of OCC is usually significantly less than 1 g Hb/dl) as administered low dosage therapeutic Hb is diluted in the circulatory pool. An alternative approach consists in addressing the increase of oxygen delivery capacity (ODC) using hyperviscous plasma expansion, which in anemia induces supra-perfusion, and increases of tissue perfusion (flow) by as much as 50%. This effect is found with polyethylene glycol conjugate albumin (PEG-Alb), which increases the shear thinning behavior of diluted blood, facilitating cardiac function. Induction of supra-perfusion exploits ODC as the product of OCC and blood flow, the outcome being independent of their relative proportions. This approach may potentially save a considerable proportion of the blood supply, with the additional benefit of enhanced tissue washout of toxic metabolites in the microcirculation, a result not achievable with oxygen therapeutics.
Last update: 24 July 2014